Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype
- First Online:
- Cite this article as:
- Brasky, T.M., Bonner, M.R., Moysich, K.B. et al. Cancer Causes Control (2011) 22: 965. doi:10.1007/s10552-011-9769-9
- 250 Downloads
Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk of breast cancer, though findings have been inconsistent. This inconsistency may result from differences in etiology for breast tumors of different subtypes. We examined the association between NSAID use and breast cancer characterized by molecular subtypes in a population-based case–control study in Western New York. Cases (n = 1,170) were women with incident, primary, histologically confirmed breast cancer. Controls (n = 2,115) were randomly selected from NY Department of Motor Vehicles records (<65 years) or Medicare rolls (≥65 years). Participants answered questions regarding their use of aspirin and ibuprofen in the year prior to interview and their use of aspirin throughout their adult life. Logistic regression models estimated odds ratios (OR) and 95% confidence intervals (95% CI). Recent and lifetime aspirin use was associated with reduced risk, with no differences by subtype. Recent use of ibuprofen was significantly associated with increased risk of ER+/PR+(OR 1.33, 95% CI: 1.09–1.62), HER2− (OR 1.27, 95% CI: 1.05–1.53), and p53− breast cancers (OR 1.28, 95% CI: 1.04–1.57), as well as luminal A or B breast cancers. These findings support the hypothesis of heterogeneous etiologies of breast cancer subtypes and that aspirin and ibuprofen vary in their effects.